United States Patent [19]

Ginnaga et al.

[11] **Patent Number: 4,563,303**

[45] **Date of Patent: Jan. 7, 1986**

[54] **METHOD FOR PURIFICATION OF FILAMENTOUS HEMAGGLUTININ**

[75] Inventors: **Akihiro Ginnaga; Shin Sakuma; Tsukasa Nishihara; Tomitaka Tashiro; Sadao Susumi; Tetsuo Kawahara; Hiroshi Mizokami,** all of Kumamoto, Japan

[73] Assignee: **Judicial Foundation The Chemosero-Therapeutic Research Institute,** Kumamoto, Japan

[21] Appl. No.: **722,381**

[22] Filed: **Apr. 12, 1985**

[30] **Foreign Application Priority Data**

Apr. 14, 1984 [JP] Japan 59-075314
Apr. 25, 1984 [JP] Japan 59-084778
May 7, 1984 [JP] Japan 59-091631

[51] **Int. Cl.**[4] **C07G 7/00;** A61K 39/10

[52] **U.S. Cl.** ..... **260/112 R;** 424/92; 435/822

[58] **Field of Search** ..... 260/112 R; 424/92; 435/822

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,842,061 10/1974 Andersson et al. ..... 260/112 B
3,920,625 11/1975 Andersson et al. ..... 260/112 B
4,138,287 2/1979 Andersson et al. ..... 424/89 X
4,168,300 9/1979 Andersson et al. ..... 260/112 R X
4,195,076 3/1980 Fontanges ..... 424/89 X
4,247,452 1/1981 Irons et al. ..... 260/112 R
4,247,539 1/1981 Iritani et al. 424/92
4,455,297 6/1984 Syukuda et al. 424/92
4,515,714 5/1985 Kawahara et al. ..... 260/112 R

FOREIGN PATENT DOCUMENTS

0121249 10/1984 European Pat. Off. 424/92

OTHER PUBLICATIONS

Inf. Immun., 9, 801–810 (1974), Sato et al.
Inf. Immun., 25, 460–462 (1979), Arai et al.
Inf. Immun., 31, 1223–1231 (1981), Sato et al.
Inf. Immun., 32, 243–250 (1981), Munoz et al.
Biochimica et Biophysica Acta, 659, 7–14 (1981), Turner et al.

Primary Examiner—Howard E. Schain
Attorney, Agent, or Firm—Wegner & Bretschneider

[57] **ABSTRACT**

Improved method for the purification of filamentous hemagglutinin (F-HA) on industrial scale which comprises contacting a culture of a microorganism of the genus Bordetella with a cellulose sulfate gel, a polysaccharide gel chemically bound with dextran sulfate, or a crosslinked polysaccharide sulfate gel, thereby adsorbing F-HA on the gel, and then eluting F-HA from the gel. Said method can give a highly purified F-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.

12 Claims, No Drawings